Get the Stockscreener App
41.66
0.69%
-0.295
Phibro Animal Health Corp stock is traded at $41.66, with a volume of 99,049.
It is down -0.69% in the last 24 hours and up +10.12% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$41.95
Open:
$42.14
24h Volume:
99,049
Relative Volume:
0.36
Market Cap:
$1.69B
Revenue:
$982.01M
Net Income/Loss:
$14.80M
P/E Ratio:
112.58
EPS:
0.37
Net Cash Flow:
$37.02M
1W Performance:
+3.99%
1M Performance:
+10.12%
6M Performance:
+42.52%
1Y Performance:
+91.45%
1-Day Range:
$41.59
$42.82
1-Week Range:
$40.02
$42.82
52-Week Range:
$16.16
$46.42
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAHC
Phibro Animal Health Corp
|
41.70 | 1.70B | 982.01M | 14.80M | 37.02M | 0.37 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
Campbell & CO Investment Adviser LLC Sells 28,942 Shares of Phibro Animal Health Corporation $PAHC - Defense World
Phibro Animal Health (PAHC) director sells $569k in shares - Investing.com
Phibro Animal Health (PAHC) director sells $569k in shares By Investing.com - Investing.com South Africa
Reasons to Add Fresenius Medical Stock to Your Portfolio Now - Finviz
Phibro Animal Health Stock Climbs 90.9% in a Year: What's Driving It? - Yahoo Finance
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now - Finviz
Phibro (PAHC) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Here's Why Phibro Animal Health (PAHC) is a Strong Growth Stock - Yahoo Finance
Glycolic Acid Market is expected to generate a revenue of USD 461.74 Million by 2032, Globally, at 5.73% CAGR: Verified Market Research® - GlobeNewswire Inc.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com - Investing.com India
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 - Investing.com
Assessing Phibro Animal Health (PAHC) Valuation After Recent Share Price Strength - Yahoo Finance
Is Phibro Animal Health (PAHC) Pricing Reflecting Its Strong Multi Year Share Price Performance? - Yahoo Finance
3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC) - Yahoo Finance
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148 By Investing.com - Investing.com Australia
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148 - Investing.com
Is Phibro Animal Health (PAHC) a Great Value Stock Right Now? - Yahoo Finance
Can Phibro Animal Health Corporation stock deliver consistent earnings growthFibonacci Extensions & Free Daily Stock Hotspot Analysis - ulpravda.ru
Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of “Hold” from Analysts - Defense World
Phibro Animal Health (NASDAQ:PAHC) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - Yahoo Finance
Trend Dashboard Flags Symbiox Investment Trading Co Ltd As Potential Swing TradeDividend Stability Analysis & Free Explosive Earning Power - earlytimes.in
Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of "Hold" from Analysts - MarketBeat
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
Reasons to Retain Baxter International Stock in Your Portfolio Now - Finviz
Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Phibro Animal Health (STU:PB8) EV-to-OCF : 27.56 (As of Dec. 23, 2025) - GuruFocus
Phibro Animal Health (PAHC): Assessing Valuation After a Recent Pullback and Strong Year-to-Date Rally - simplywall.st
Published on: 2025-12-21 06:36:24 - Улправда
Is Phibro Animal Health Corporation stock resilient to inflation2025 Valuation Update & Daily Profit Maximizing Trade Tips - Улправда
Phibro Animal Health (PAHC): Rethinking Valuation After a 95% Year-to-Date Surge and Recent Pullback - Yahoo Finance
Phibro Animal Health says Daniel Bendheim to assume CEO role in July - MSN
Phibro Animal Health (NASDAQ:PAHC) Shares Gap DownHere's What Happened - MarketBeat
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock - Yahoo Finance
Why hedge funds are buying Phibro Animal Health Corporation stockWeekly Gains Report & Risk Managed Investment Strategies - DonanımHaber
Is Phibro Animal Health Corporation stock a defensive play in 20252025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts - DonanımHaber
Is Phibro Animal Health Corporation stock supported by strong fundamentalsTrade Volume Summary & AI Forecast Swing Trade Picks - Улправда
Phibro Animal Health Corp. Announces Leadership Transition - citybiz
Leadership Changes at Phibro Animal Health (PAHC) Aim to Drive F - GuruFocus
Phibro Animal Health announces leadership transition - Feedstuffs
Phibro Animal Health announces CEO transition effective July 2026 - Investing.com
Phibro Animal Health Names Dani Bendheim as CEO, Jack Bendheim Becomes Executive Chairman - marketscreener.com
Phibro Animal Health Corporation Announces Chief Executive Officer Changes, Effective July 1, 2026 - marketscreener.com
Phibro Animal Health (PAHC) plans CEO handoff to Dani Bendheim in 2026 - Stock Titan
Phibro Animal Health Corporation Announces Leadership Transition - Yahoo Finance
Is It Too Late to Consider Phibro After a 95% Surge in 2025? - simplywall.st
Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? - Yahoo Finance
Phibro Animal Health (PAHC) CEO details Rule 10b5-1 insider stock sales - Stock Titan
Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance
Research Analysts Set Expectations for PAHC FY2026 Earnings - MarketBeat
Is Phibro Animal Health Still Attractive After a 94% Surge in 2025? - Yahoo Finance
Why is Phibro (PAHC) down 5.3% since last earnings report? - MSN
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phibro Animal Health Corp Stock (PAHC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENDHEIM JACK | President and CEO |
Jan 14 '26 |
Sale |
40.53 |
3,651 |
147,983 |
47,457 |
| BENDHEIM JACK | President and CEO |
Jan 15 '26 |
Sale |
40.02 |
2,932 |
117,348 |
44,525 |
| BENDHEIM JACK | President and CEO |
Jan 09 '26 |
Sale |
40.16 |
213 |
8,554 |
38,659 |
| BENDHEIM JACK | President and CEO |
Jan 07 '26 |
Sale |
40.09 |
328 |
13,149 |
38,872 |
| BENDHEIM JACK | President and CEO |
Dec 11 '25 |
Sale |
40.93 |
5,752 |
235,405 |
39,200 |
| BENDHEIM JACK | President and CEO |
Dec 08 '25 |
Sale |
40.06 |
3,520 |
141,018 |
46,240 |
| BENDHEIM JACK | President and CEO |
Dec 09 '25 |
Sale |
40.19 |
1,288 |
51,763 |
44,952 |
| BENDHEIM JACK | President and CEO |
Dec 04 '25 |
Sale |
41.22 |
3,520 |
145,096 |
49,760 |
| BENDHEIM JACK | President and CEO |
Dec 03 '25 |
Sale |
40.77 |
3,520 |
143,511 |
53,280 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):